The company aims to provide solutions to address local pain and infections in complex wounds. Credit: NONGASIMO / Shutterstock.

Wound care technology developer Imbed Biosciences has announced the appointment of Terry Bromley as its new chief executive officer (CEO).

With a career spanning over three decades in the medical device and regenerative medicine sectors, Bromley’s ‘expertise’ is expected to contribute to the company’s growth and uphold its commitment to enhancing patient outcomes through soft tissue repair solutions.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Imbed Biosciences founder and chief scientific officer Ankit Agarwal said: “Terry brings a wealth of commercial leadership experience in the wound and skin care sector, delivering innovation and building high-performing teams.

“His expertise will be invaluable as we navigate the next phase of our company’s growth with our Microlyte Matrix technology platform. I’m excited to welcome Terry to the Imbed Biosciences family.”

Before his recent appointment at Imbed, Bromley held the position of Avita Medical‘s commercial operations and global sales senior vice-president (SVP).

In this role, he spearheaded the regenerative tissue commercial teams and was pivotal in expanding the company’s commercial capabilities both in the US and internationally.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

His experience also includes working as Crawford Healthcare’s SVP and general manager, where he was pivotal in establishing and commercialising the US business unit within the wound and skin care markets.

Additionally, his previous roles included senior director of marketing and business development in Emergent BioSolutions’ healthcare protective products division.

After spending nearly two decades at ConvaTec, a unit of Bristol Myers Squibb, Bromley progressed through various leadership roles and was instrumental in steering strategic portfolio and commercialisation initiatives, particularly for the unit’s wound and burn care technologies.

Bromley said: “Imbed’s differentiated platform technology uniquely positions the company to make a meaningful impact on the healthcare industry.”

Leveraging its Microlyte Matrix technology platform, Imbed aims to provide solutions to address local pain and infections in complex wounds.